

# LUPIN LIMITED

## SAFETY DATA SHEET

### Section 1: Identification

#### Section 1, Identification

<b>Material</b>	<b>Clonidine Hydrochloride Extended-Release Tablets 0.1 mg</b>
<b>Manufacturer</b>	<b>Lupin Limited</b> Nagpur 441108 India
<b>Distributor</b>	Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202 United States Tel. 001-410-576-2000 Fax. 001-410-576-2221

### Section 2: Hazard(s) Identification

#### Section 2, Hazard(s) identification

<b>Fire and Explosion</b>	Expected to be non-combustible.
<b>Health</b>	Clonidine hydrochloride extended-release tablets are contraindicated in patients with a history of a hypersensitivity reaction to clonidine. Reactions have included generalized rash, urticaria, and angioedema.
<b>Environment</b>	No information is available about the potential of this product to produce adverse environmental effects.

### Section 3: Composition/Information on Ingredients

#### Section 3, Composition/information on ingredients

<b>Ingredients</b>	<b>CAS</b>
Clonidine Hydrochloride USP	4205-91-8

### Section 4: First-Aid Measures

#### Section 4, First-aid measures

<b>Ingestion</b>	Rinse mouth. Drink plenty of water. Call a physician immediately.
<b>Inhalation</b>	Keep patient calm, remove to fresh air, seek medical attention.
<b>Skin Contact</b>	Wash off thoroughly with ample water. Seek medical attention.
<b>Eye Contact</b>	Seek Immediately wash affected eyes for at least 15 minutes under running water with eyelids held open, consult an eye specialist.

## NOTES TO HEALTH PROFESSIONALS

### Medical Treatment

Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

### OVERDOSAGE

Hypertension may develop early and may be followed by hypotension, bradycardia, respiratory depression, hypothermia, drowsiness, decreased or absent reflexes, weakness, irritability and miosis. The frequency of CNS depression may be higher in children than adults. Large overdoses may result in reversible cardiac conduction defects or dysrhythmias, apnea, coma and seizures. Signs and symptoms of overdose generally occur within 30 minutes to two hours after exposure.

Consult with a Certified Poison Control Center (1-800-222-1222) for up-to-date guidance and advice.

## Section 5: Fire-Fighting Measures

### Section 5, Fire-fighting measures

#### Fire and Explosion Hazards

Assume that this product is capable of sustaining combustion.

#### Extinguishing Media

Use extinguishing media appropriate to surrounding fire conditions, such as water, fog, spray, dry chemical, regular foam, carbon dioxide.

#### Special Firefighting Procedures

For single units (packages): No special requirements needed.  
For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.

#### Hazardous Combustion Products

Hazardous combustion or decomposition products are expected when the product is exposed to fire.

## Section 6: Accidental Release Measures

### Section 6, Accidental release measures

#### Personal Precautions

Wear personal protective equipment.  
Keep people away from and upwind of spill/leak.  
Ensure adequate ventilation.  
Knock down dust with water spray jet.  
Suppress vapours with waterspray.

#### Environmental Precautions

Do not flush into surface water or sanitary sewer system.

#### Clean-up Methods

Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Clean-up methods - large spillage  
Dampen, pick up mechanically and dispose of.  
Clean-up methods - small spillage  
Use approved industrial vacuum cleaner for removal.  
Keep in suitable, closed containers for disposal.

## Section 7: Handling and Storage

### Section 7, Handling and storage

<b>Handling</b>	No special control measures required for the normal handling of this product.
<b>Storage</b>	Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. Dispense in a tight container.

## Section 8: Exposure Controls/Personal Protection

### Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

## Section 9: Physical and Chemical Properties

### Section 9, Physical and chemical properties

<b>Physical Form</b>	Clonidine hydrochloride extended-release tablets are white to off white round shaped biconvex tablets, debossed with 'LU' on one side and 'Z55' on other side.  NDC 68180-606-06 – 0.1 mg round tablets supplied in bottles containing 30 tablets. NDC 68180-606-07 – 0.1 mg round tablets supplied in bottles containing 60 tablets. NDC 68180-606-09 – 0.1 mg round tablets supplied in bottles containing 90 tablets.
----------------------	--

## Section 10: Stability and Reactivity

### Section 10, Stability and reactivity

Stable under recommended storage conditions.

## Section 11: Toxicological Information

### Section 11, Toxicological information

#### Carcinogenesis, Mutagenesis, Impairment of Fertility

Clonidine HCl was not carcinogenic when administered in the diet of rats (for up to 132 weeks) or mice (for up to 78 weeks) at doses of up to 1620 (male rats), 2040 (female rats), or 2500 (mice) mcg/kg/day. These doses are approximately 20, 25, and 15 times, respectively, the maximum recommended human dose (MRHD) of 0.4 mg/day on a mg/m<sup>2</sup> basis.

There was no evidence of genotoxicity in the Ames test for mutagenicity or mouse micronucleus test for clastogenicity.

In a reproduction study fertility of female rats appeared to be adversely affected at dose levels of 500 and 2000 mcg/kg/day (10 and 40 times the MRHD on a mg/ m<sup>2</sup> basis). Lower doses have not been adequately evaluated and a no adverse effect level could not be established.

## Section 12: Ecological Information

### Section 12: Ecological Information

No relevant studies identified.

## Section 13: Disposal Considerations

### Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

## Section 14: Transport Information

### Section 14: Transport Information

#### IATA/ICAO - Not Regulated

IATA Proper shipping Name	:	N/A
IATA UN/ID No:N/A	:	N/A
IATA Hazard Class:N/A	:	N/A
IATA Packaging Group:N/A	:	N/A
IATA Label	:	N/A

#### IMDG - Not Regulated

IMDG Proper shipping Name	:	N/A
IMDG UN/ID No	:	N/A
IMDG Hazard Class	:	N/A
IMDG Flash Point	:	N/A
IMDG Label	:	N/A

#### DOT - Not Regulated

IMDG Proper shipping Name	:	N/A
IMDG UN/ID No	:	N/A
IMDG Hazard Class	:	N/A
IMDG Flash Point	:	N/A
IMDG Label	:	N/A

## Section 15: Regulatory Information

### Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

## Section 16: Other Information

### Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

**Lupin** shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.